ApprovalTrail

Approval · Notice of Compliance 24106 · 2020

BRILINTA: Notice of Compliance 24106

Issued August 26, 2020

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number
24106
Date
August 26, 2020
Company
Astrazeneca Canada IncMississauga, Ontario, Canada
Product type
Prescription Pharmaceutical
Submission
Supplement to a New Drug Submission (SNDS), supplement
Submission class
Other
Reason
To add a new indication to the product monograph

Products in this notice

BrandDINStatus today
BRILINTANot yet assigned—

Medicinal ingredients